Determining the effect of Myo-inositol on outcome of assisted reproductive technology cycles

Effect of Myo-Inositol Supplementation on Clinical Outcomes in Women Undergoing Assisted Reproductive Technology (ART)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241122063802N6

Enrollment

Registered

2026-04-15

Start date

2026-04-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: Intervention group: This group will receive 2000 micrograms of myo-inositol (Inofolic sachet, Lo. Li Pharma. Tehran, Iran) along with 200 micrograms of folic acid (Raha pharmaceutical

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Candidates for ICSI/IVF treatment for any indication except AMH < 1 Triple-line endometrium with thickness greater than 8 mm before embryo transfer

Exclusion criteria

Exclusion criteria: Presence of any underlying disease (metabolic or endocrine disorders) Uterine anomalies Frozen embryo transfer cycles

Design outcomes

Primary

Measure	Time frame
Number of retrieved oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Quality of retrieved oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Number of MII (metaphase II) oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Number of degenerated oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.	—

Measure

Time frame

Number of retrieved oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Quality of retrieved oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Number of MII (metaphase II) oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.;Number of degenerated oocytes. Timepoint: During oocyte retrieval. Method of measurement: Under a microscope by an embryologist.

—

Secondary

Measure	Time frame
Chemical pregnancy rate. Timepoint: After embryo transfer. Method of measurement: Positive ß-hCG result.;Clinical pregnancy rate. Timepoint: After embryo transfer. Method of measurement: Ultrasound.;Spontaneous miscarriage rate. Timepoint: After embryo transfer. Method of measurement: Ultrasound.;Live birth rate. Timepoint: After delivery. Method of measurement: Follow up for the pregnancy outcome.	—

Measure

Time frame

Chemical pregnancy rate. Timepoint: After embryo transfer. Method of measurement: Positive ß-hCG result.;Clinical pregnancy rate. Timepoint: After embryo transfer. Method of measurement: Ultrasound.;Spontaneous miscarriage rate. Timepoint: After embryo transfer. Method of measurement: Ultrasound.;Live birth rate. Timepoint: After delivery. Method of measurement: Follow up for the pregnancy outcome.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Sattarpour

Tabriz University of Medical Sciences

rezasattarpour.tums@gmail.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026